Lexeo Therapeutics, Inc. - Common Stock (LXEO)

$13.85 0.17 (1.21%)

16:00 EDT LXEO Stock Quote Delayed 30 Minutes

LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023

By InvestorPlace Earnings Dec 11, 2023

Lexeo Therapeutics just reported results for the third quarter of 2023.

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 50,716

Day's Range $13.72 - $14.28

52-Week Range $9.00 - $22.33

Dividend & Yield N/A (N/A)

LXEO Stock Predictions, Articles, and Lexeo Therapeutics, Inc. - Common Stock News

From the Web

Lexeo gets orphan drug, fast track status for cardiac gene therapy (NASDAQ:LXEO)

From Seeking Alpha Dec 18, 2023

Lexeo Therapeutics (LXEO) has received FDA orphan drug and fast track designations for its gene therapy LX2020 in the treatment of arrhythmogenic cardiomyopathy. Read more here.

Stifel starts Lexeo at buy, cites ataxia and Alzheimer's drug candidates (LXEO)

From Seeking Alpha Nov 30, 2023

Stifel initiates coverage of Lexeo Therapeutics (LXEO) with a buy rating, citing its drug candidates for Friedreich's ataxia and Alzheimer's disease. Read more here.

JP Morgan starts Lexeo at overweight, sees upside with continued de-risking (NASDAQ:LXEO)

From Seeking Alpha Nov 30, 2023

JP Morgan initiated coverage of Lexeo Therapeutics (LXEO) with an overweight rating, citing potential upside from continued de-risking of its drug candidates. Read more here.

RBC starts Lexeo at outperform, cites Friedreich's ataxia drug opportunity (NASDAQ:LXEO)

From Seeking Alpha Nov 29, 2023

RBC Capital Markets has initiated coverage of Lexeo Therapeutics (LXEO) with an outperform rating, citing the company’s management team and commercial opportuni

Lexeo Therapeutics shares down 8% after downsized $100M IPO (LXEO)

From Seeking Alpha Nov 3, 2023

Shares of Lexeo Therapeutics (LXEO) dropped 8% after a downsized $100M IPO that priced below its previously proposed range.

Lexeo Therapeutics sets terms for proposed $126M IPO (LXEO)

From Seeking Alpha Oct 30, 2023

Lexeo Therapeutics (LXEO) plans to raise $126M in its initial public offering, offering 9M shares priced between $13 and $15. Read more here.

ADVERTISEMENT